A protein promotes carbohydrate and lipid metabolism in obese mice within one third of fat loss in 18 days
October 31, 2018 Source: Science and Technology Daily Author: Liu Haiying
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Researchers at Georgetown University in the United States published a research report in the Science Report on the 29th, saying that a protein naturally occurring in human body, fibroblast growth factor (FGF) binding protein 3, has a strong metabolic regulation ability. Significantly promotes carbohydrate and lipid metabolism. Experiments have shown that forced expression of this protein can reduce the fat mass of obese mice by a third in the short term.
FGF is a polypeptide that exists from worms to various human organisms and is involved in various biological processes such as cell growth and wound healing. The researchers found that in the FGF family, three FGFs are involved in metabolic control, with FGF19 and FGF21 involved in regulating the storage and use of carbohydrates and fats, and FGF23 controlling phosphate metabolism. When these FGFs bind to the so-called "chaperone protein" BP3 to form fibroblast growth factor binding protein 3, their ability to control metabolism is significantly enhanced, becoming a powerful driving force for carbohydrate and lipid metabolism.
Mouse experiments have shown that induction of fibroblast growth factor binding protein 3 forced expression can reduce fat in obese mice by more than one-third in 18 days. At the same time as fat loss, some obesity-related diseases in mice, such as hyperglycemia and fatty liver, are also reduced. Clinical and microscopic examination of the treated mice showed no side effects from this treatment.
Researchers have pointed out that obesity is a major driver of metabolic syndrome and has become an important health problem affecting the world, affecting 650 million people worldwide. Their new research shows that fibroblast growth factor binding protein 3 is expected to be a drug candidate for the treatment of metabolic diseases, providing a new means for the treatment of type 2 diabetes, non-alcoholic fatty liver disease and other diseases.
Volsen owns a professional custom synthesis department, with more than 15 senior scientific research chemical personnels who have a graduate degree or above. We also have an independent scientific management system. Our company integrates years of production experiences and talent reserves that forms a strong R&D production capacity, furthermore we could undertake various chemicals customizations from kg to ton relying on the existing production base and equipment.
With the accumulated strong expertise,and experiences of developments,we have developed the products with good quality and also manufactured the intermediates for multi-national pharmaceutical company.
R&D Pharmaceutical, Research And Development Pharmaceutical, Bulk Drug Development
Taizhou Volsen Chemical Co., Ltd. , https://www.volsenchem.com